GSK3B and early-onset autosomal dominant Alzheimer disease: Furthermore,this neuropeptide was able to partially block somatostatin(SRIF) depletion induced by amyloid β (Aβ) in the temporalcortex.8,25 Some studies show that Glypromate mimicsthe effects of IGF-1 on the SRIF system through a mechanism otherthan Aβ clearance such as modulation of calcium and glycogensynthase kinase 3β (GSK-3β) signaling pathway.8,25 These results are relevant since the reduction of SRIF is implicatedin Alzheimer’s disease (AD), as does the GSK-3β.8,25